aibio
Listings ·
COSCIENS Biopharma files Form 15 to end SEC reporting duties
The July 6, 2026 notice lists approximately 153 holders of record of its common shares.
CSCI COSCIENS Biopharma Inc.
COSCIENS Biopharma (CSCI) news CSCI delisting news
Latest COSCIENS Biopharma news
- Listings
COSCIENS Biopharma, delisted from Nasdaq in September, applies for OTCQB quotation
COSCIENS plans to file a Form 15-F to end its U.S. reporting and has applied for OTCQB quotation. It had $8.5 million of cash on September 30, 2025, and its net loss narrowed to $1.8 million in the quarter.
- Listings
COSCIENS Biopharma files Form 25 to withdraw its shares from Nasdaq
COSCIENS marked the voluntary withdrawal box on its Nasdaq Form 25. The form gives no reason, and the company's April 2025 annual report describes a failed Phase 3 trial and a shift to natural-based products.
Questions about COSCIENS Biopharma
Was COSCIENS Biopharma delisted?
Our latest story on this, dated Nov 12, 2025: "COSCIENS Biopharma, delisted from Nasdaq in September, applies for OTCQB quotation". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of COSCIENS Biopharma?
COSCIENS Biopharma Inc. trades under the ticker CSCI on TSX.
Where is COSCIENS Biopharma listed?
COSCIENS Biopharma Inc. is listed on TSX. Our directory also records these other listings: GETTEX:ET80; LSX:A42DUX; OTC:CSCIF.
What is the SEC CIK of COSCIENS Biopharma?
The SEC Central Index Key (CIK) for COSCIENS Biopharma Inc. is 1113423. Its filings are on SEC EDGAR.
How many shares does COSCIENS Biopharma have outstanding?
3,183,330 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-25.
Which country or territory is COSCIENS Biopharma listed under?
Our directory records COSCIENS Biopharma Inc. under Canada.
What does COSCIENS Biopharma do?
Our directory classifies COSCIENS Biopharma Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of COSCIENS Biopharma?
The ISIN recorded for COSCIENS Biopharma Inc. is CA22112H2000.
Does aibio.space cover COSCIENS Biopharma?
aibio.space lists COSCIENS Biopharma Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is COSCIENS Biopharma incorporated?
SEC records list its state or country of incorporation as A6.
What is the latest COSCIENS Biopharma (CSCI) stock news?
Our latest story on COSCIENS Biopharma, dated Jul 6, 2026: "COSCIENS Biopharma files Form 15 to end SEC reporting duties". The July 6, 2026 notice lists approximately 153 holders of record of its common shares. Source.
How much cash does COSCIENS Biopharma have?
From our story of Nov 12, 2025: It had $8.5 million of cash on September 30, 2025, and its net loss narrowed to $1.8 million in the quarter. Source.
Is COSCIENS Biopharma a smaller reporting company?
SEC records list COSCIENS Biopharma Inc.'s filer category as: Non-accelerated filer.
Where is COSCIENS Biopharma headquartered?
SEC records list its business address as C/O NORTON ROSE FULBRIGHT CANADA LLP, TORONTO, Ontario, Canada, M5K 1E7.
When does COSCIENS Biopharma's fiscal year end?
COSCIENS Biopharma Inc.'s fiscal year ends on December 31, per SEC records.
Investor discussion: COSCIENS Biopharma
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Filed to end its SEC reporting. SEC Form 15-12G. Source
- Listings
Reported a reverse stock split. SEC Form 6-K. Source
- Distress
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 6-K. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
- Listings
Filed to remove its shares from exchange listing. SEC Form 25. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
- Listings
Reported a reverse stock split. SEC Form 6-K. Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. Source
Stock chart
SEC filings and registration
- SEC name
- COSCIENS Biopharma Inc.
- CIK
- 1113423
- Industry (SIC)
- Perfumes, Cosmetics & Other Toilet Preparations (2844)
- US tickers
- CSCIF (OTC)
- State or country of incorporation
- A6
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer
- Business address
- C/O NORTON ROSE FULBRIGHT CANADA LLP, TORONTO, Ontario, Canada, M5K 1E7
- Phone
- 843-900-3201
- Shares outstanding
- 3,183,330 as of 2025-12-31 (20-F filed 2026-03-25)
- Former names
- Aeterna Zentaris Inc.; AETERNA LABORATORIES INC
Recent filings
Listing details
- Company
- COSCIENS Biopharma Inc.
- Ticker
- CSCI
- Listing
- TSX
- Country or territory
- Canada
- Business scope
- Pharmaceuticals: Major
- ISIN
- CA22112H2000
- Other listed symbols
- GETTEX:ET80; LSX:A42DUX; OTC:CSCIF
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction